203 related articles for article (PubMed ID: 36110944)
21. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting.
Sands J; Subramanian J
Front Oncol; 2023; 13():1161931. PubMed ID: 38221913
[TBL] [Abstract][Full Text] [Related]
22. Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme.
Alexander M; Rogers J; Parakh S; Mitchell P; Clay TD; Kao S; Hughes BGM; Itchins M; Kong BY; Pavlakis N; Solomon BJ; John T
Intern Med J; 2024 Feb; ():. PubMed ID: 38369719
[TBL] [Abstract][Full Text] [Related]
23. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
Boyne DJ; Dawe DE; Shakir H; Joe-Uzuegbu O; Farah E; Pabani A; Baratta C; Brenner DR; Cheung WY
Target Oncol; 2023 Sep; 18(5):697-705. PubMed ID: 37656263
[TBL] [Abstract][Full Text] [Related]
24. A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study.
Fudio S; Pérez-Ramos L; Asín-Prieto E; Zeaiter A; Lubomirov R
Front Oncol; 2023; 13():1152371. PubMed ID: 37397388
[TBL] [Abstract][Full Text] [Related]
25. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
[TBL] [Abstract][Full Text] [Related]
26. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
Kundu K; Cardnell RJ; Zhang B; Shen L; Stewart CA; Ramkumar K; Cargill KR; Wang J; Gay CM; Byers LA
Transl Lung Cancer Res; 2021 Nov; 10(11):4095-4105. PubMed ID: 35004241
[TBL] [Abstract][Full Text] [Related]
27. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
28. De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways.
Chakraborty S; Coleman C; Manoj P; Demircioglu D; Shah N; de Stanchina E; Rudin CM; Hasson D; Sen T
Clin Cancer Res; 2023 Sep; 29(17):3526-3540. PubMed ID: 37382635
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
[TBL] [Abstract][Full Text] [Related]
30. Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
Rittberg R; Leung B; Al-Hashami Z; Ho C
Curr Oncol; 2022 Dec; 29(12):9744-9752. PubMed ID: 36547179
[TBL] [Abstract][Full Text] [Related]
31. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
[TBL] [Abstract][Full Text] [Related]
32. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Das M; Padda SK; Weiss J; Owonikoko TK
Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
[TBL] [Abstract][Full Text] [Related]
33. Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Fernández-Teruel C; Fudio S; Lubomirov R
Cancer Chemother Pharmacol; 2022 May; 89(5):585-594. PubMed ID: 34739582
[TBL] [Abstract][Full Text] [Related]
34. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Kristeleit R; Leary A; Delord JP; Moreno V; Oaknin A; Castellano D; Shappiro GI; Fernández C; Kahatt C; Alfaro V; Siguero M; Rueda D; Zeaiter A; Awada A; Santaballa A; Zaman K; Sehouli J; Subbiah V
Invest New Drugs; 2023 Oct; 41(5):677-687. PubMed ID: 37556023
[TBL] [Abstract][Full Text] [Related]
35. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Metaxas Y; Kahatt C; Alfaro V; Fudio S; Zeaiter A; Plummer R; Sessa C; Von Moos R; Forster M; Stathis A
Invest New Drugs; 2022 Feb; 40(1):91-98. PubMed ID: 34453241
[TBL] [Abstract][Full Text] [Related]
37. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience.
Hagmann R; Hess V; Zippelius A; Rothschild SI
J Cancer; 2015; 6(11):1148-54. PubMed ID: 26516363
[TBL] [Abstract][Full Text] [Related]
38. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
39. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
40. Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma.
Gadducci A; Cosio S
Front Oncol; 2022; 12():914342. PubMed ID: 36408147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
